Literature DB >> 12557297

Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS.

Wenhua Zhang1, Malini Narayanan, Robert M Friedlander.   

Abstract

The known neuroprotective effects of minocycline and creatine in animal models of amyotrophic lateral sclerosis (ALS) led us to examine whether the combination of these agents would result in increased neuroprotection. As previously reported, we confirmed in ALS mice that either minocycline or creatine treatment results in improvement in motor performance and extended survival. We report that combination of minocycline and creatine resulted in additive neuroprotection, suggesting this to be a novel potential strategy for the treatment of ALS. To our knowledge, this is the first report demonstrating additive neuroprotection of a combinatorial approach in a mouse model of ALS. Adding relevancy to our findings, minocycline and creatine, are relatively safe, cross the blood-brain barrier, and are currently available for human evaluation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12557297     DOI: 10.1002/ana.10476

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  42 in total

1.  Creatine and antioxidant treatment prevent the inhibition of creatine kinase activity and the morphological alterations of C6 glioma cells induced by the branched-chain alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Cláudia Funchal; Patrícia Fernanda Schuck; André Quincozes Dos Santos; Maria Caroline Jacques-Silva; Carmem Gottfried; Regina Pessoa-Pureur; Moacir Wajner
Journal:  Cell Mol Neurobiol       Date:  2006-02       Impact factor: 5.046

2.  Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials.

Authors:  Albert C Ludolph; Sarah Jesse
Journal:  Ther Adv Neurol Disord       Date:  2009-09       Impact factor: 6.570

Review 3.  [Amyotrophic lateral sclerosis. Current clinical trials and underlying pathomechanisms].

Authors:  K Kollewe; R Dengler; S Petri
Journal:  Nervenarzt       Date:  2008-06       Impact factor: 1.214

Review 4.  Redox modifier genes and pathways in amyotrophic lateral sclerosis.

Authors:  Barrie J Carter; Pervin Anklesaria; Stephanie Choi; John F Engelhardt
Journal:  Antioxid Redox Signal       Date:  2009-07       Impact factor: 8.401

5.  Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.

Authors:  Namita Agrawal; Judit Pallos; Natalia Slepko; Barbara L Apostol; Laszlo Bodai; Ling-Wen Chang; Ann-Shyn Chiang; Leslie Michels Thompson; J Lawrence Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

6.  Caspases as therapeutic targets in Alzheimer's disease: is it time to "cut" to the chase?

Authors:  Troy T Rohn; Elizabeth Head
Journal:  Int J Clin Exp Pathol       Date:  2008-06-10

Review 7.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

8.  Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis.

Authors:  Yi Zhang; Anna Cook; Jinho Kim; Sergei V Baranov; Jiying Jiang; Karen Smith; Kerry Cormier; Erik Bennett; Robert P Browser; Arthur L Day; Diane L Carlisle; Robert J Ferrante; Xin Wang; Robert M Friedlander
Journal:  Neurobiol Dis       Date:  2013-03-26       Impact factor: 5.996

9.  Role of creatine supplementation on exercise-induced cardiovascular function and oxidative stress.

Authors:  Michael Kingsley; Daniel Cunningham; Laura Mason; Liam P Kilduff; Jane McEneny
Journal:  Oxid Med Cell Longev       Date:  2009 Sep-Oct       Impact factor: 6.543

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.